PDPN and cancer: 3) and need to care the side effect in developing anti-podoplanin mAb as a therapeutic drug. In that sense, LpMab series, cancer-specific antibodies recognizing cancerous aberrant glycosylated podoplaninan, are potent for therapeutics [96]. Some anti-podoplanin mAbs may be useful as diagnostic tools to identify patients with podoplanin-positive tumor, as higher sensitivity than generally used D2-40, anti-podoplanin mAb [97].